. Author manuscript; available in PMC: 2011 Sep 14.

Published in final edited form as: Am J Geriatr Psychiatry. 2005 Jun;13(6):491–500. doi: 10.1176/appi.ajgp.13.6.491

TABLE 1. Demographic and Pretreatment Clinical Characteristics of the Randomized Sample.

	Placebo (N = 37)	Naltrexone (N = 37)	Test Statistic	p
Age, years	62.5 (5.6)	64.2 (6.9)	t = −1.17	0.248
Male, %	81.1	78.4	χ²=0.08	0.772
Caucasian, %	64.9	67.6	χ²=0.06	0.806
Recruitment site, % VA	29.7	32.4	χ²=0.06	0.802
Ham-D	23.4 (5.0)	20.1 (5.7)	t=2.60	0.011
Days heavy drinking, %	75.8 (29.1)	59.2 (35.6)	t=2.190	0.032
Days drinking, %	82.4 (24.5)	75.5 (29.3)	t=1.11	0.270
Drinks/drinking day	10.2 (6.8)	6.5 (3.9)	t=2.84	0.006
ASI Alcohol Score	0.67 (0.18)	0.64 (0.17)	t=0.79	0.433
PCS	43.8 (8.5)	46.1 (10.3)	t = −0.99	0.325
MCS	33.2 (9.6)	38.1 (11.5)	t = −1.91	0.061
With primary depression, %	68.6	65.7	χ²=0.07	0.799

Note: Those subjects randomized to placebo had significantly greater depressive symptoms and pretreatment heavy-drinking days. Values are mean (standard deviation) for continuous measures and percentages for categorical measures.

Ham-D: Hamilton Rating Scale for Depression; ASI: Addiction Severity Index; PCS: Physical Component Score from the Medical Outcomes Scale (SF-36); MCS: Mental Component Score from the Medical Outcomes Scale (SF-36).